
Our Vision, Mission, and Culture
Building a team dedicated to transforming regenerative medicine
Founded on Scientific Excellence
Mesenbio emerged from decades of pioneering research in mesenchymal stem cells and extracellular vesicles (EVs). Our founding team recognised that the transformative potential of EV therapeutics was being held back by fundamental manufacturing challenges, and we set out to solve this critical bottleneck.
Our vision is to lead a new era in regenerative medicine by unlocking the full potential of EVs and delivering life-changing therapies enabled by consistent, scalable EV production through our FT‑01 platform.
Why Now: A Critical
Inflection Point
Mesenbio has reached a pivotal milestone in establishing FT-01 as a licensing-ready EV production platform. With scalable manufacturing demonstrated and therapeutic proof-of-concept achieved in rheumatoid arthritis, we're positioned for clinical translation and strategic partnerships.
Our recent achievements include significant scale-up of FT-01-derived EV production with an 84% reduction in cost of goods, establishment of a proprietary EV platform prepared for GMP-grade manufacturing, and robust preclinical data demonstrating MEV-N01's therapeutic potential.
Driving Innovation Through Shared Principles
We are driven by scientific excellence, collaboration, ethical responsibility, and innovation. We conduct rigorous research, partner with experts, and prioritise ethical advancements to transform discoveries into real-world biotech solutions.
Our Values
Ethical
Our dedication to advancing regenerative medicine is intertwined with a consciousness of wider-reaching consequences.
Supportive
We foster talent through continuous learning and personal development for individual and collective growth.
Passionate Together
Dedicated individuals bring excitement and curiosity to help us push boundaries. Our shared goals unite us and empower individuals to contribute to the success of the team.
Respectful
We believe that no professional environment can exist without candour, transparency, and accountability
Leadership Team
Regenerative Biology and Biotech Expertise
Management Team
-
Dr. David Kuntin
Chief Executive Officer
David brings a proven track record of translating academic innovation into commercial success, with strong expertise in process development strategy and biotech company leadership.
-
Prof. Paul Genever
Chief Scientific Officer
Paul's 100+ peer-reviewed publications in regenerative medicine and proven success leading industry-academic partnerships provide the scientific foundation for our platform development.
-
Dr. David Simpson
Chair
With 25+ years of biotech and pharma leadership experience, David provides deep expertise in therapeutic commercialisation and strategic guidance for our platform development.
-
Anita Adams
Finance Director
+25 years’ experience supporting startups/scaleups/fast growing entities
Expert in strategic finance, scaling businesses, cashflow management and growth planning. -
Jason Goldstein
Director
Partner and co-founder, NG Bio. 10 years experience in life science company creation with focus on inflammation. MBA from LBS, Chartered Accountant.
Technical Leadership
-
Dr. Dave Mentlak
Senior Scientist
Dave's expertise in cell-based bioprocessing and upstream development drives our manufacturing excellence, with strong capabilities in cell biology and discovery research.
-
Dr. Ryan Farley
Scientist II
Ryan specialises in downstream process development and EV analytics, ensuring the quality and characterisation systems that underpin FT-01's consistency advantages.
World-Class Advisory Network
Strategic Guidance from Industry Leaders
Our advisory board brings together clinical expertise, industry experience, and regulatory knowledge essential for successful platform development and therapeutic translation.
Advisory Members Include
-
Prof. John Isaacs
Consultant Rheumatologist, Freeman Hospital Professor of Clinical Rheumatology, Newcastle University
Associate Medical Director for Research, Newcastle Hospitals -
Prof. Rose Maciewicz
Professor, University of Glasgow
7+ years VP Strategy Respiratory & iMed, Astrazeneca -
Dr. Panteli Theocharous
Chief Therapeutics Officer, Stratus Therapeutics, 15+ years at PPD, Janssen
-
Dimor Elbers
Associate Director, Licensing, Lonza
17+ years at Lonza
Strong manufacturability and business development expertise
Join Our Mission
We're building a team of exceptional individuals united by our shared commitment to transforming regenerative medicine. If you're passionate about translating breakthrough science into therapeutic impact, we'd like to hear from you.